Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

被引:130
作者
Abdul-Aziz, Mohd H. [1 ]
Lipman, Jeffrey [1 ,2 ]
Mouton, Johan W. [3 ,4 ]
Hope, William W. [5 ]
Roberts, Jason A. [1 ,2 ,5 ]
机构
[1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[3] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[4] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
[5] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
基金
英国医学研究理事会;
关键词
antibiotic; resistance; pharmacodynamics; pharmacokinetics; antibiotic dosing; INTENSIVE-CARE-UNIT; MUTANT SELECTION WINDOW; MINIMUM INHIBITORY CONCENTRATION; VENTILATOR-ASSOCIATED PNEUMONIA; VITRO DYNAMIC-MODEL; COMBINATION ANTIMICROBIAL THERAPY; INFECTIOUS-DISEASES SOCIETY; STAPHYLOCOCCUS-AUREUS MRSA; IN-VITRO; PSEUDOMONAS-AERUGINOSA;
D O I
10.1055/s-0034-1398490
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The recent Surge in multidrug-resistant pathogens combined with the diminishing antibiotic pipeline has treated a growing need to optimize the use of our existing antibiotic armamentarium, particularly in the management of intensive tare unit (ICU) patients. Optimal and timely pharrnacokinetic/pharmacodynamic (PK/PD) target attainment has been associated with an increased likelihood of clinical and microbiological success in critically ill patients. Emerging data, mostly from in vitro and in vivo studies, suggest that optimization of antibiotic therapy should not only aim to Maximize clinical outcomes but also to include the suppression of resistance. The development of antibiotic dosing regimens that adheres to the PK/PD principles may prolong the clinical lifespan of our existing antibiotics by minimizing the emergence of resistance. This article summarizes the relevance of PK/PD characteristics of different antibiotic classes on the development of antibiotic resistance. On the basis of the available data, we propose dosing recommendations that can be adopted in the clinical setting, to maximize therapeutic success and limit the emergence of resistance in the ICU.
引用
收藏
页码:136 / 153
页数:18
相关论文
共 219 条
[1]   Continuous beta-lactam infusion in critically ill patients: the clinical evidence [J].
Abdul-Aziz, Mohd H. ;
Dulhunty, Joel M. ;
Bellomo, Rinaldo ;
Lipman, Jeffrey ;
Roberts, Jason A. .
ANNALS OF INTENSIVE CARE, 2012, 2
[2]  
Abdul-Aziz MH, 2012, MINERVA ANESTESIOL, V78, P94
[3]   Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion [J].
Adembri, Chiara ;
Fallani, Stefania ;
Cassetta, Maria Iris ;
Arrigucci, Silvia ;
Ottaviano, Alessandra ;
Pecile, Patrizia ;
Mazzei, Teresita ;
De Gaudio, Raffaele ;
Novelli, Andrea .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (02) :122-129
[4]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[5]   Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1665-1670
[6]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[8]  
[Anonymous], 2007, CLIN INFECT DIS, DOI DOI 10.1086/520991
[9]   Pharmacokinetics and pharmacodynamics of meropenern in febrile neutropenic patients with bacteremia [J].
Ariano, RE ;
Nyhlén, A ;
Donnelly, JP ;
Sitar, DS ;
Harding, GKM ;
Zelenitsky, SA .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) :32-38
[10]  
ARISE, 2007, Crit Care Resusc, V9, P8